Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · IEX Real-Time Price · USD
8.79
-0.96 (-9.90%)
At close: Jul 19, 2024, 4:00 PM
8.95
+0.16 (1.88%)
Pre-market: Jul 22, 2024, 7:30 AM EDT
Summit Therapeutics Employees
Summit Therapeutics had 105 employees as of December 31, 2023. The number of employees increased by 28 or 36.36% compared to the previous year.
Employees
105
Change (1Y)
28
Growth (1Y)
36.36%
Revenue / Employee
n/a
Profits / Employee
-$1,105,000
Market Cap
6.17B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 105 | 28 | 36.36% |
Dec 31, 2022 | 77 | -33 | -30.00% |
Dec 31, 2021 | 110 | 29 | 35.80% |
Dec 31, 2020 | 81 | 11 | 15.71% |
Dec 31, 2019 | 70 | 9 | 14.75% |
Dec 31, 2018 | 61 | -15 | -19.74% |
Dec 31, 2017 | 76 | 36 | 90.00% |
Dec 31, 2016 | 40 | 3 | 8.11% |
Dec 31, 2015 | 37 | 14 | 60.87% |
Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Grifols | 23,737 |
Acadia Healthcare Company | 23,500 |
Bausch + Lomb | 13,300 |
Elanco Animal Health | 9,800 |
Stevanato Group | 5,634 |
HealthEquity | 3,150 |
Exelixis | 1,310 |
Glaukos | 907 |
SMMT News
- 18 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors - Business Wire
- 6 weeks ago - Summit Therapeutics stock rallies as institutional buyer loads up on shares - Invezz
- 7 weeks ago - Summit Raises $200 Million; Also Expands License Territories for Ivonescimab - Business Wire
- 7 weeks ago - Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA - Business Wire
- 7 weeks ago - Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy - Business Wire
- 7 weeks ago - Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster - Market Watch
- 7 weeks ago - Summit Therapeutics cancer therapy succeeds in late-stage China study - Reuters